Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD

Henrik Svedsater, Peter Dale, Karl Garrill, Richard Walker, Mark W Woepse, Henrik Svedsater, Peter Dale, Karl Garrill, Richard Walker, Mark W Woepse

Abstract

Background: Medications for respiratory disorders including asthma and chronic obstructive pulmonary disease (COPD) are typically delivered to the lung by means of a handheld inhaler. Patient preference for and ability to use the inhaler may influence their adherence to maintenance therapy, and adherence may affect treatment outcomes. In this study, patient experience of using a dry powder inhaler (DPI), the ELLIPTA™ DPI, in clinical trials of a new maintenance therapy for asthma and COPD was investigated. The ELLIPTA DPI has been designed to contain two separate blister strips from which inhalation powder can be delivered, and to be simple to use with a large, easy-to-read dose counter.

Methods: Semi-structured, in-depth, qualitative interviews were carried out 2-4 weeks after patients had completed one of six phase IIIa clinical trials using the ELLIPTA DPI. Interview participants were asked about their satisfaction with various attributes of the inhaler and their preference for the ELLIPTA DPI relative to currently-prescribed inhalers, and responses were explored using an inductive content analysis approach. Participants also rated the performance of the inhaler on several criteria, using a subjective 1-10 scale.

Results: Participants with asthma (n = 33) and COPD (n = 42) reported high levels of satisfaction with the ELLIPTA DPI. It was frequently described as straightforward to operate and easy to use by interview participants. Ergonomic design, mouthpiece fit, and dose counter visibility and ease of interpretation emerged as frequently cited drivers of preference for the ELLIPTA DPI compared with their current prescribed inhaler. Of participants with asthma, 71% preferred the ELLIPTA DPI to DISKUS™ and 60% to metered dose inhalers. Of participants with COPD, 86% preferred the ELLIPTA DPI to DISKUS, 95% to HandiHaler™, and 85% to metered dose inhalers. Overall average performance scores were >9 (out of 10) in participants with asthma and COPD.

Conclusion: The ELLIPTA DPI was associated with high patient satisfaction and was preferred to other inhalers by interview participants with asthma and COPD. The development of an inhaler that is regarded as easy and intuitive to use may have positive implications for adherence to therapy in asthma and COPD.

Trial registration: ClinicalTrials.gov NCT01009463 NCT01017952 NCT01053988 NCT01054885 NCT01165138 NCT01431950.

Figures

Figure 1
Figure 1
Overall performance scores. COPD = chronic obstructive pulmonary disorder.
Figure 2
Figure 2
Asthma performance scores by subgroup defined by: A) asthma severity; B) age. Note: asthma severity scores in A range from 1 (not at all severe) to 10 (extremely severe).
Figure 3
Figure 3
COPD performance scores by subgroup defined by: A) COPD severity; B) age; C) prior DPI use. Note: COPD severity scores in A range from 1 (not at all severe) to 10 (extremely severe). COPD = chronic obstructive pulmonary disorder; DPI = dry powder inhaler.

References

    1. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;13:66–74. doi: 10.1183/09059180.00008111.
    1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence and future trends. Lancet. 2007;13:765–773. doi: 10.1016/S0140-6736(07)61380-4.
    1. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol. 2004;13:191–195.
    1. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J COPD. 2010;13:401–406.
    1. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention Updated 2012. Available at: . Accessed: 2 October 2013.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines on COPD Diagnosis, Prevention and Management. Updated 2013. Available at: . Accessed: 2 October 2013.
    1. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;13:593–604. doi: 10.1016/j.rmed.2007.11.003.
    1. Virchow JC, Crompton GK. Dal Negro R, Pedersen S, Magnan A, Seidenberg J, Barnes PJ: Importance of inhaler devices in the management of airway disease. Respir Med. 2008;13:10–19. doi: 10.1016/j.rmed.2007.07.031.
    1. Small M, Anderson P, Vickers A, Kay S, Fermer S. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;13:202–212. doi: 10.1007/s12325-010-0108-4.
    1. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;13:930–938. doi: 10.1016/j.rmed.2011.01.005.
    1. Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;13:939–943. doi: 10.1136/thx.2009.113662.
    1. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat M, Versnel J, Shanahan ER, Hillyer EV, Tunsäter A, Bjermer L. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008;13:1681–1693. doi: 10.1016/j.rmed.2008.08.003.
    1. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;13:1. doi: 10.1186/1471-2466-10-1.
    1. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;13:831–838. doi: 10.1136/thx.2007.086041.
    1. Charles MS, Blanchette CM, Silver H, Lavallee D, Dalal AA, Mapel D. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin. 2010;13:2421–2429. doi: 10.1185/03007995.2010.516284.
    1. Emilsson M, Berndtsson I, Lötvall J, Millqvist E, Lundgren J, Johansson Å, Brink E. The influence of personality traits and beliefs about medicines on adherence to asthma treatment. Prim Care Respir J. 2011;13:141–147. doi: 10.4104/pcrj.2011.00005.
    1. Dekhuijzen R, Magnan A, Kneussl M. The ADMIT series – issues in inhalation therapy. 1) The goals of asthma treatment – can they be achieved? Prim Care Respir J. 2007;13:341–348.
    1. Morris NR, Sabapathy S, Adams L, Kingsley RA, Schneider DA, Stulbarg MS. Verbal numerical scales are as reliable and sensitive as visual analog scales for rating dyspnea in young and older subjects. Respir Physiol Neurobiol. 2007;13:360–365. doi: 10.1016/j.resp.2007.01.006.
    1. Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nursing. 2008;13:107–115. doi: 10.1111/j.1365-2648.2007.04569.x.
    1. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;13:334. doi: 10.1002/1098-240X(200008)23:4<334::AID-NUR9>;2-G.
    1. Capstick TGD, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;13:91–103. doi: 10.1586/ers.11.89.
    1. Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Scheuch G, Bousquet J. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013;13:37–46. doi: 10.1016/j.rmed.2012.09.017.
    1. Papi A, Haughney J, Virchow JC, Roche N, Palkonen S, Price D. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J. 2011;13:982–985. doi: 10.1183/09031936.00150910.
    1. Leiva-Fernández F, Leiva-Fernández J, Zubeldia-Santoyo F, García-Ruiz A, Prados-Torres D, Barnestein-Fonseca P. Efficacy of two educational interventions about inhalation techniques in patients with chronic obstructive pulmonary disease (COPD). TECEPOC: study protocol for a partially randomized controlled trial (preference trial) Trials. 2012;13:64. doi: 10.1186/1745-6215-13-64.
    1. Horne R. Adherence to asthma medication: a question of ability? Prim Care Respir J. 2011;13:118–119. doi: 10.4104/pcrj.2011.00054.
    1. Roy A, Battle K, Lurslurchachai L, Halm EA, Wisnivesky JP. Inhaler device, administration technique, and adherence to inhaled corticosteroids in patients with asthma. Prim Care Respir J. 2011;13:148–154. doi: 10.4104/pcrj.2011.00022.
    1. World Health Organization (WHO) Adherence to Long-Term Therapies: Evidence for Action. 2003. Available at: . Accessed: 2 October 2013.
    1. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL. Medication adherence issues in patients treated for COPD. Int J COPD. 2008;13:371–384.
    1. Jäger L, Laurikainen K, Leinonen M, Silvasti M. Beclomethasone dipropionate Easyhaler is as effective as budesonide Turbuhaler in the control of asthma and is preferred by patients. German Study Group. Int J Clin Pract. 2000;13:368.
    1. van Schayk CP, Bijl Hofland ID, Folgering H, Cloosterman SGM, Akkermans R, Elshout FVD, van Weel C. Influence of two different inhalation devices on therapy compliance in asthmatic patients. Scand J Prim Health Care. 2002;13:126.
    1. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J COPD. 2009;13:381–390.
    1. George J, Kong DCM, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest. 2005;13:3198–3204. doi: 10.1378/chest.128.5.3198.
    1. Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J COPD. 2011;13:353–363.
    1. Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;13:109–116. doi: 10.1183/09059180.05.00009606.
    1. Burnell PKP, Malton A, Reavill K, Ball MHE. Design, validation and initial testing of the Electronic Lung™ device. J Aerosol Sci. 1998;13:1011–1025. doi: 10.1016/S0021-8502(97)10039-8.
    1. Hamilton M, Prime D, Bogalo Huescar M, Pang C, Charles S, Gillett B. In–vitro delivery performance of umeclidinium and umeclidinium/vilanterol from a dry powder inhaler using the Electronic Lung breathing simulator to replicate inhalation profiles from patients with varying COPD severity. Am J Respir Crit Care Med. 2013;13:A4281.
    1. Svedsater H, Jacques L, Goldfrad C, Bleecker ER, O'Byrne PM, Woodcock A. Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. Eur Respir J. 2013;13(Suppl 57):128s–129s.
    1. Verver S, Poelman M, Bögels A, Chisholm SL, Dekker FW. Effects of instruction by practice assistants on inhaler technique and respiratory symptoms of patients. A controlled randomized videotaped intervention study. Fam Pract. 1996;13:35–40. doi: 10.1093/fampra/13.1.35.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir